FDA expands indication for Titan Spine's Endoskeleton
This article was originally published in Clinica
Executive Summary
The US FDA has expanded the labelling of Titan Spine's Endoskeleton to include its use as an interbody fusion device. Its previous 510(k) clearance in September 2003 covered its use for vertebral body replacement. Mequon, Wisconsin-based Titan explained that the device was previously used to replace bone, but can now also replace spinal discs. The new indication is for skeletally-mature patients with degenerative disc disease at one or two contiguous levels from the second lumbar to the first sacral vertebra, who have already received six months of non-operative treatment. Titan hopes the expanded indication will increase adoption of the product, and estimates that 65 million people in the US have some type of degenerative disc condition.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.